SEOUL, Apr. 23 (Korea Bizwire) — Celltrion Inc. saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday. The combined market share of Remsima and the subcutaneous version of the drug hit 74 percent in Britain, Germany, France, Spain and Italy [...]
SEOUL, Feb. 14 (Korea Bizwire) — Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday. Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data. Remsima references Janssen [...]
SEOUL, June 10 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that it will begin a study on the treatment efficacy of its biosimilar Remsima on the novel coronavirus. Celltrion Healthcare, which handles Celltrion’s overseas business, said the trial study of Remsima, a biosimilar drug to treat autoimmune diseases, [...]